21 closest matches · ranked by relevance
Venezuelan Equine Encephalitis · Western Equine Encephalitis · Eastern Equine Encephalitis
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants
Eastern Equine Encephalitis
Primary: Subject Response Rates for PRNT80 Titers — 39; 28; 48; 79 Participants
Japanese Encephalitis
Primary: Percentage of Participants With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 98.0; 99.3; 100.0; 100.0 percentage of participants
Encephalitis, Japanese B
Primary: Seroconversion Rate After Primary Vaccination — 100 percentage of seroconversion
Japanese Encephalitis
Primary: Number and Percentage of Subjects With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 14; 243; 233; 24 Participants
Japanese Encephalitis · Japanese Encephalitis Vaccine
Primary: Change of T Lymphocyte Responses to Live Attenuated JE SA-14-14-2 Vaccine at Week 2. — 34 IFNγ SFC/million PBMC
Encephalitis · Japanese Encephalitis
Primary: Number of Participants With Japanese Encephalitis Seroconversion After Vaccination With One Dose of Either Japanese Encephalitis Chimeric Vaccine (JE-CV) or Japanese…
Japanese Encephalitis
Primary: Number of Participants With Treatment Emergent Adverse Events Following Vaccination With Either ChimeriVax™ JE or JE Inactivated Mouse Brain Derived Vaccine — 2; 2; 1; 0…
Japanese Encephalitis
Primary: Number of Participants Who Seroconverted to the Respective Homologous JE Vaccine Strain Up to 28 Days After the First Active Vaccination With Either ChimeriVax™-JE or…
Encephalitis, Japanese B
Primary: Percentage of Participants With Seroprotection for Measles 4 Weeks After Vaccination — 1.1; 0.0; 0.0; 88.6 percentage of participants
Japanese Encephalitis
Primary: Number of Participants With Japanese Encephalitis (Homologous Virus) Seroconversion Following Either ChimeriVax™-JE or JE-Vax® Vaccination — NA; 324; 273; 343 Participants
Japanese Encephalitis
Primary: Primary: Plasmablast Percentage of Total B Cells at 7 Days Post Vaccine — 1.36; 1.96; 1.69 percent plasmablasts of B cells
Japanese Encephalitis · Japanese Encephalitis Virus Disease
Primary: Percentage of Participants With Seroconversion to Japanese Encephalitis Chimeric Virus Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis…
Dengue Fever · Zika · Vector-Borne Diseases
Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants
Japanese Encephalitis · Measles · Mumps
Primary: Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or…
Encephalitis, Japanese B
Primary: Measles Seropositivity at 24 and 36 Months — 98.92; 95.75; 94.37; 94.62 percentage of participants seropositive
Japanese Encephalitis · Varicella
Primary: Percentage of Participants With JE Seroprotection Before and Following a Dose of Live Attenuated JE-CV — 80.3; 0; 96.2; 15.4 Percentage of participants
West Nile Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies to Vaccination With ChimeriVax™ WN02 or a Placebo Vaccine — 5.00; 5.76; 5.06; 5.22 Titers
Encephalitis · Japanese Encephalitis
Primary: Percentage of Participants With Japanese Encephalitis Seroprotection Following a Single Dose of JE-CV — 2.6; 100.0; 88.2; 90.0 Percentage of participants
Japanese Encephalitis
Primary: Percentage of Subjects With Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer (PRNT) — 81.8 percentage of subjects
Japanese Encephalitis
Primary: SCR (Seroconversion Rate)of IC51 Compared to JE-VAX at Day 56 — 96.4; 93.6 percentage of participants